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An old story, favored by editors, describes a ﬁshmon-
ger’s sign that says “Fresh Fish Sold Here.” But the
sign is verbose: “fresh” is unnecessary, because no
ﬁshmonger would sell ﬁsh that was anything but fresh.
“Here” is also redundant. Where else but at the shop
would the ﬁsh be for sale? “Sold” is not needed either,
because no one would expect the ﬁsh to be given away.
Whether “Fish” is needed is debatable, because, as the
story goes, you can smell it a mile away.
The report in this issue by the ISPOR Task Force on
Real World Data brought this story to mind. The Task
Force was asked by ISPOR “to develop a framework
to assist health care decision-makers in dealing with
‘real world’ data and information in ‘real world’ health
care decision-making, especially related to coverage
and payment decisions.” In their deliberations they
wrestled with the deﬁnition of “real world data,” as
well they might. In the discussion about what data to
use, the phrase “real world” is meant to signify a
particular category of data. The word “real” is unnec-
essary to this phrase, as any health researcher would
obviously be focused on reality rather than fantasy.
So should data be “world” data, or not? What is the
alternative?
The Task Force decided to deﬁne “real world data”
as “data used for decision making that are not col-
lected in conventional randomized controlled trials.”
Why should it even be necessary to make a case for
using data outside of trials? Apparently it is necessary
because trials have assumed such a lofty status in bio-
medical research. It is not without some reason that
randomized trials are often viewed as the pinnacle of
research endeavor. They are extremely powerful tools
for addressing speciﬁc scientiﬁc questions. Random
assignment makes it possible to eliminate alternative
explanations for observed associations that may be
extremely hard to rule out using “real world data.” In
addition, the rigorous protocol routinely applied in
randomized trials reduces variability from clinical indi-
cations, dosing schedules, adjunct therapies, and many
other sources, all of which can undermine the interpre-
tation of ﬁndings in settings that lack such rigor in who
is studied and how their disease is treated.
For these reasons, trials are rightly viewed as one of
the strongest research tools available to biomedical
researchers. But we must be careful not to exaggerate
the role that randomized trials play in the accumula-
tion of knowledge generally. Some consider the ran-
domized trial to be a gold standard for research that is
requisite for contributing solid knowledge, arguing
that proof of a hypothesis can only be established from
a randomized trial. This view is too extreme, fostering
confusion about how science works. Watson and Crick
did not need randomized trials to infer the structure of
DNA, nor did John Snow need a trial to demonstrate
that drinking water contaminated with sewage was
strikingly associated with cholera occurrence. Further-
more, how can trials constitute “proof” when several
trials of the same intervention can result in divergent
results? If trials really provided proof, one trial for
every treatment would sufﬁce.
The reality is that trials can be controversial, mutu-
ally contradictory, or irreproducible. Further, philoso-
phers have agreed for centuries that no empirical
hypothesis can be proven, in the sense of logical cer-
tainty, by any experiment or any observation. The
inability to achieve certain knowledge, however, is no
barrier to the accumulation of knowledge. Although
trials can be instrumental to studying many phenom-
ena, progress in science does not depend absolutely
on the ability to conduct randomized trials. Indeed,
without ever resorting to a single randomized trial,
scientists have developed a rich body of knowledge in
areas as diverse as plate tectonics, the evolution of
species, astronomy, and the effects of cigarette smoking
on human health. Thus, although randomized trials
are powerful tools, they should be viewed as merely
one very useful technique for framing observations
intended to address a particular question.
Trials are often designed to evaluate treatment efﬁ-
cacy in a narrow setting. The narrowness of that setting
is often considered a liability for a trial, because it limits
generalizability of the results. To achieve greater gener-
alizability, many studies are designed to have study
populations that are broadly representative of target
populations, as in population surveys. Representative-
ness in a trial, however, conﬂicts with the aim of nar-
rowing the range of variables that might affect the study
result, a goal in experimentation that supersedes repre-
sentativeness. Just as mouse researchers would prefer to
have identical mice in their experiments than to have
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mice that are representative of all mice, trials are
scientiﬁcally stronger with homogeneous patient po-
pulations rather than broadly representative study
populations. The reason is that the internal compari-
sons of the experimental study are more important than
an attempt to generalize the study results through sta-
tistical inference. The whole point of experimental
science is to narrow the range of inﬂuences and zone in
on what happens in highly controlled and delineated
circumstances.
Furthermore, it is a futile hope that simply by study-
ing a broad range of subjects, one then can apply to the
results to people with that broad range of characteris-
tics. Instead, with a mix of participants, one gets a mix
of results. If the study ﬁndings vary across subgroups,
a representative study population tells nothing about
that variation; it merely gives the average across those
groups. If knowing that average is the goal of the
study, representativeness of study subjects with respect
to a given variable may be desirable. If, instead, the
goal is to assess the efﬁcacy of an intervention, the ﬁrst
hurdle may be to learn what the intervention can do in
those who might beneﬁt the most from it. Learning the
average effect across a broader spectrum of patients
might be a reasonable goal for future study. Thus,
an ideal trial of a new intervention is usually better
designed with less, rather than more representative-
ness, to reduce confounding by some risk factors and
to focus the study on a patient population that might
beneﬁt most.
Unless a trial is designed from the start to evaluate
coverage and payment, it is unlikely to provide ideal
data on these facets of intervention to inform broader
policy or business decisions. Typically a trial is of only
marginal use to evaluate questions that are not closely
related to the study aims. In most instances, research-
ers studying diverse health outcomes must look
beyond trials and trial data. Outside of trials one ﬁnds
what the Task Force has termed “real world data.”
Studies drawn from the everyday experience of
patients who are members of broadly deﬁned popula-
tions face serious challenges. But if astronomers can
look to the stars and learn about the universe and do
so without conducting any randomized trials, surely
health researchers can contribute to knowledge using
data beyond those from randomized trials. Fortu-
nately, with sufﬁcient care, such data can be organized
into sound studies that yield solid inferences. The
report on Real World Data in this issue provides a
useful summary of the opportunities, difﬁculties and
intricacies of moving beyond trial data to study health
outcomes.
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